Pradeep Bist

Dr. Pradeep Bist

orcid

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 March 2024 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
AMAndrea Mencarelli
Andrea Mencarelli
Pradeep BistPradeep Bist
Pradeep Bist
Hae Woong ChoiHae Woong Choi
Hae Woong Choi
HKHanif Javanmard Khameneh
Hanif Javanmard Khameneh
AMAlessandra Mortellaro
Alessandra Mortellaro
Soman AbrahamSoman Abraham
Soman Abraham

26 October 2026 in Viruses
Verified
Journal Article
Open access
PDF file
JOJithesh Othayoth
Jithesh Othayoth
JBJayant Singh Bist
Jayant Singh Bist
Pradeep BistPradeep Bist
Pradeep Bist
Antiviral inhibition does not produce a single therapeutic endpoint: some infections can be cured after finite treatment, others require durable suppression, and others remain difficult to influence because the actionable phase is brief or anatomically inaccessible. These different outcomes reflect the biological state that preserves infection or permits return, the time during which a drug-sensitive process remains causally important, the anatomical space in which consequential virus or viral material resides, and the capacity of viral populations to evolve under therapeutic pressure. Here, we examine these relationships across curable, suppressible, latent, acute, neuroinvasive, and post-acute viral infections. Comparisons among HCV, HIV-1, HBV, HSV, influenza, RSV, dengue, SARS-CoV-2, Ebola virus, CHIKV, and other systems show how persistence architecture, diagnostic timing, tissue pharmacology, host context, and resistance can determine whether antiviral activity translates into virological cure, durable suppression, recurrence control, prevention, or incomplete therapeutic control. Human challenge studies, clinical programs with discordant outcomes, and resistance studies further illustrate where mechanistic activity and therapeutic sufficiency diverge. Across these examples, antiviral outcome depends ultimately on whether treatment can intercept the biological state that determines the subsequent fate of infection.

21 February 2025 in Research Square
Verified
Preprint
Open access
PDF file
OGOlivia Goethals
Olivia Goethals
DBDoortje Borrenberghs
Doortje Borrenberghs
KCKitti Chan
Kitti Chan
SBSven Van Brandt
Sven Van Brandt
SJSteffen Jaensch
Steffen Jaensch
Anil KoulAnil Koul
Anil Koul
Flaviviruses, such as dengue virus (DENV), Zika virus (ZIKV), West Nile virus (WNV), Japanese encephalitis virus (JEV), and yellow fever virus (YFV), constitute a significant public health concern with billions of people at risk of infection. Climate change and the expanding geographical distribution of mosquito vectors transmitting flaviviruses have increased their potential to cause large-scale disease outbreaks. The frequency and severity of disease outbreaks highlights the urgent need for a broad-spectrum antiviral agent targeting flaviviruses. In this work, we conducted a comprehensive morphological profiling of approximately 200,000 small molecules through a fluorescence-based high-content imaging platform, which led to the identification of a singular small molecule exhibiting broad-spectrum activity against flaviviruses. Subsequent hit deconvolution against DENV serotype 2 (DENV-2) revealed NS2A as a novel therapeutic target and suggested a mechanism whereby the identified small molecule inhibits the interaction between NS2A and the prM protein, revealing a previously uncharacterized antiviral mechanism of action.

1 September 1999 in Archives of Virology
Verified
Journal Article
Closed access
PDF file
VSV. V. S. Suryanarayana
V. V. S. Suryanarayana
SVS. Viswanathan
S. Viswanathan
GRG. Ratish
G. Ratish
Pradeep BistPradeep Bist
Pradeep Bist
KPK. Prabhudas
K. Prabhudas
CNC. Natarajan
C. Natarajan